Court ruling may open access, decrease costs for breast cancer gene test
A ruling by the Supreme Court that human genes can't be patented is expected to increase access and drop the cost for tests for gene mutations that greatly raise the risk of developing breast or ovarian cancer. In a bit of a mixed message, the court unanimously decided that certain types of gene tests may still be protected by patents, yet it struck down patents that a company has long held for BRCA genes. The company makes the only test for two of those breast cancer genes, BRCA1 and BRCA2. “It appears that it will allow the market to open up so that other laboratories can offer the test,” said Rebecca Nagy, a genetics counselor at Ohio State University and president of the National Society of Genetic Counselors. And that should make the tests cheaper and available to more women, she said. Hours after the ruling, one company - DNATraits, part of Houston-based Gene By Gene, Ltd. - said it would offer BRCA gene testing in the United States for $995 - less than a third of the current price. A primer on the case: Q: What did the court say? …